1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Global Multiple Myeloma Partnering 2010-2015

Global Multiple Myeloma Partnering 2010-2015

  • July 2015
  • -
  • Currentpartnering
  • -
  • 150 pages

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

The Multiple Myeloma Partnering 2010-2015 provides understanding and access to the multiple myeloma partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of multiple myeloma partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors multiple myeloma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 60 links to online copies of actual multiple myeloma deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of multiple myeloma partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in multiple myeloma partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading multiple myeloma deals since 2010. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of multiple myeloma partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of multiple myeloma technologies and products.

Report scope

Multiple Myeloma Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to multiple myeloma trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in multiple myeloma dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 60 multiple myeloma contract documents
The leading multiple myeloma deals by value since 2010
In Multiple Myeloma Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.Multiple Myeloma Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of multiple myeloma deal trends since 2010
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 60 actual multiple myeloma deals entered into by the world’s biopharma companies since 2010
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Global Multiple Myeloma Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in multiple myeloma partnering

2.1. Introduction
2.2. Multiple myeloma partnering over the years
2.3. Big pharma multiple myeloma dealmaking activity
2.4. Big biotech multiple myeloma dealmaking activity
2.5. Most active multiple myeloma dealmakers
2.6. Multiple myeloma partnering by deal type
2.7. Multiple myeloma partnering industry sector
2.8. Multiple myeloma partnering by stage of development
2.9. Multiple myeloma partnering by technology type
2.10. Disclosed financial deal terms for multiple myeloma
2.10.1 Multiple myeloma headline values
2.10.2 Multiple myeloma upfront payments
2.10.3 Multiple myeloma milestone payments
2.10.4 Multiple myeloma royalty rates

Chapter 3 - Leading multiple myeloma deals

3.1. Introduction
3.2. Top multiple myeloma deals by value

Chapter 4 - Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type

Chapter 5 - Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Multiple myeloma partnering since 2010
Figure 2: Big pharma - top 50 - multiple myeloma deals 2010 to 2015
Figure 3: Big pharma multiple myeloma deal frequency - 2010 to 2015
Figure 4: Big biotech - top 50 - multiple myeloma deals 2010 to 2015
Figure 5: Big biotech multiple myeloma deal frequency - 2010 to 2015
Figure 6: Multiple myeloma dealmaking activity- 2010 to 2015
Figure 7: Multiple myeloma partnering by deal type since 2010
Figure 8: Multiple myeloma partnering by industry sector since 2010
Figure 9: Multiple myeloma partnering by stage of development since 2010
Figure 10: Multiple myeloma partnering by technology type since 2010
Figure 11: Multiple myeloma deals with a headline value
Figure 12: Multiple myeloma deals with upfront payment values
Figure 13: Multiple myeloma deals with milestone payments
Figure 14: Multiple myeloma deals with royalty rates, %
Figure 15: Top multiple myeloma deals by value since 2010
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...


Download Unlimited Documents from Trusted Public Sources

Cancer and Breast Cancer Statistics in Switzerland

  • February 2017
    138 pages
  • Cancer  

    Breast Cancer  

    Obesity  

  • Switzerland  

View report >

Hormone and Therapy Market in Pakistan and the US

  • February 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Endocrine Disease Statistics in the US

  • February 2017
    115 pages
  • Endocrine Disea...  

    Diabetes Monito...  

    Hospital  

  • United States  

    North America  

View report >

Cancer Statistics

4 days ago

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.